These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Host immune response against Scedosporium species. Roilides E; Simitsopoulou M; Katragkou A; Walsh TJ Med Mycol; 2009 Jun; 47(4):433-40. PubMed ID: 19184770 [TBL] [Abstract][Full Text] [Related]
27. Treatment of fungal and other opportunistic infections in immunocompromised patients. Wade JC Leukemia; 1997 May; 11 Suppl 4():S38-9. PubMed ID: 9179282 [TBL] [Abstract][Full Text] [Related]
28. Invasive fungal infection in the immunosuppressed host. Salit I; Hand R Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):267-76. PubMed ID: 1158537 [TBL] [Abstract][Full Text] [Related]
29. Prevention of invasive fungal infections in patients with neoplastic disease. Walsh TJ; Lee JW Clin Infect Dis; 1993 Nov; 17 Suppl 2():S468-80. PubMed ID: 8274613 [TBL] [Abstract][Full Text] [Related]
30. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Ellis M Mol Immunol; 2002 May; 38(12-13):947-57. PubMed ID: 12009573 [TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for fungal infections. Segal BH; Kwon-Chung J; Walsh TJ; Klein BS; Battiwalla M; Almyroudis NG; Holland SM; Romani L Clin Infect Dis; 2006 Feb; 42(4):507-15. PubMed ID: 16421795 [TBL] [Abstract][Full Text] [Related]
32. Proinflammatory cytokines and treatment of disease. VAN DER Meer JWM; Vogels MTE; Netea MG; Kullberg BJ Ann N Y Acad Sci; 1998 Sep; 856():243-251. PubMed ID: 9917883 [TBL] [Abstract][Full Text] [Related]
33. The role of complement in invasive fungal infections. Speth C; Rambach G; Lass-Flörl C; Dierich MP; Würzner R Mycoses; 2004 Apr; 47(3-4):93-103. PubMed ID: 15078425 [TBL] [Abstract][Full Text] [Related]
34. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Chamilos G; Kontoyiannis DP Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387 [TBL] [Abstract][Full Text] [Related]
35. Immunology of Fungal Infections. Fernández-García OA; Cuellar-Rodríguez JM Infect Dis Clin North Am; 2021 Jun; 35(2):373-388. PubMed ID: 34016282 [TBL] [Abstract][Full Text] [Related]
36. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Walsh TJ; Hiemenz JW; Anaissie E Infect Dis Clin North Am; 1996 Jun; 10(2):365-400. PubMed ID: 8803625 [TBL] [Abstract][Full Text] [Related]
37. Mononuclear phagocyte-mediated antifungal immunity: the role of chemotactic receptors and ligands. Swamydas M; Break TJ; Lionakis MS Cell Mol Life Sci; 2015 Jun; 72(11):2157-75. PubMed ID: 25715741 [TBL] [Abstract][Full Text] [Related]
38. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Anaissie E Clin Infect Dis; 1992 Mar; 14 Suppl 1():S43-53. PubMed ID: 1562695 [TBL] [Abstract][Full Text] [Related]
39. [Drug resistance in the treatment of invasive fungal infections]. Nordøy I; Gaustad P Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376 [TBL] [Abstract][Full Text] [Related]
40. Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy. Vonk AG; Netea MG; van der Meer JW; Kullberg BJ Expert Opin Biol Ther; 2006 Sep; 6(9):891-903. PubMed ID: 16918256 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]